摘要
目的分析达格列净联合胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂治疗在2型糖尿病伴肥胖患者中应用效果。方法选取2022年7月—2024年7月福建省德化县医院收治的104例2型糖尿病伴肥胖患者,根据不同治疗方案分为参考组(52例,给予达格列净治疗)和联用组(52例,参考组基础上采用利拉鲁肽治疗)。比较两组腰围及体重指数、血糖、胰岛功能、血脂及不良反应发生情况。结果治疗后,联用组的腰围、体重指数、空腹血糖、餐后2 h血糖、糖化血红蛋白、空腹胰岛素、胰岛素抵抗指数、胰岛β细胞功能指数、总胆固醇、甘油三酯和低密度脂蛋白均优于参考组,差异均有统计学意义(P均<0.05)。两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论达格列净与GLP-1受体激动剂联合应用,能有效控制2型糖尿病伴肥胖患者体重,并改善血糖、胰岛功能以及血脂水平。
Objective To analyze the application effect of dapagliflozin combined with glucagon-like peptide-1(GLP-1)receptor agonist in the treatment of type 2 diabetes mellitus with obesity.Methods A total of 104 patients with type 2 diabetes mellitus and obesity admitted to Dehua County Hospital of Fujian Province from July 2022 to July 2024 were selected and divided into reference group(52 cases,treated with dapagliflozin)and combination group(52 cases,treated with liraglutide on the basis of the reference group)according to different treatment schemes.The waist circumference,body mass index,plasma glucose,islet function,blood lipid and the occurrence of adverse reactions were compared between the two groups.Results After treatment,the waist circumference,body mass index,fasting plasma-glucose,2-hour postprandial plasma glucose,glycated hemoglobin A1c,fasting insulin,insulin resistance index,isletβ-cell function index,total cholesterol,triglyceride and low-density lipoprotein in the combination group were better than those in the reference group,and the differences were statistically significant(all P<0.05).There was no statistically significant difference in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion The combined application of dapagliflozin and GLP-1 receptor agonist can effectively control the body weight of patients with type 2 diabetes mellitus and obesity,and improve the plasma glucose,insulin function and blood lipid levels.
作者
李进庆
LI Jinqing(Department of Pharmacy,Dehua County Hospital of Fujian Province,Quanzhou 362500,Fujian,China)
出处
《糖尿病新世界》
2025年第16期103-106,共4页
Diabetes New World
